Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Vertex Pharmaceuticals revenue increased from $4.2 billion in 2019 to $6.2 billion in 2020, a (49.1%) increase.

Annual Revenue ($)

Vertex Pharmaceuticals revenue was $6.21 b in FY, 2020 which is a (49.1%) year over year increase from the previous period.

Quarterly Revenue ($)

FY, 2018FY, 2019FY, 2020
Revenue$3.05 b$4.16 b$6.21 b
Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021
Revenue$858.44 m$941.29 m$949.83 m$1.52 b$1.52 b$1.54 b$1.72 b

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Vertex Pharmaceuticals revenue breakdown by business segment: 12.9% from KALYDECO, 14.6% from ORKAMBI, 10.1% from SYMDEKO/SYMKEVI and 62.3% from TRIKAFTA/KAFTRIO

FY, 2020FY, 2019FY, 2018
KALYDECO$802.87 m$991.06 m$1.01 b
ORKAMBI$907.51 m$1.33 b$1.26 b
SYMDEKO/SYMKEVI$628.58 m$1.42 b$768.66 m
TRIKAFTA/KAFTRIO $3.86 b$420.11 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu